This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. [Internet]. Lyon, France: International Agency for Research on Cancer 2013. [Citated 2015 Sep 30] Available at: http://globocan.iarc.frFerlayJSoerjomataramIErvikMDikshitREserSMathersCGLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase, No. 11[Internet]. Lyon, France: International Agency for Research on Cancer2013Citated 2015 Sep 30] Available athttp://globocan.iarc.frSearch in Google Scholar
D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v116-9.D’AddarioGFrühMReckMBaumannPKlepetkoWFelipEMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v116910.1093/annonc/mdq18920555059Search in Google Scholar
Vansteenkiste J, Ruysscher D De, Eberhardt WEE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi89-98.VansteenkisteJDe RuysscherDEberhardtWEELimESenanSFelipEEarly and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi899810.1093/annonc/mdt24123860613Search in Google Scholar
Cufer T, Ovcaricek T, O’Brien MER. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2013; 49: 1216-25.CuferTOvcaricekTO’BrienMERSystemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-yearsEur J Cancer20134912162510.1016/j.ejca.2012.11.02123265700Search in Google Scholar
Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-47.YehETHBickfordCLCardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and managementJ Am Coll Cardiol20095322314710.1161/01.CIR.0000133187.74800.B915226229Search in Google Scholar
Albini A, Pennesi G, Donatelli F, Cammarota R, Flora S De, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardiooncological prevention. J Natl Cancer Inst 2010; 102: 14-25.AlbiniAPennesiGDonatelliFCammarotaRDe FloraSNoonanDMCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardiooncological preventionJ Natl Cancer Inst2010102142510.1093/jnci/djp440280228620007921Search in Google Scholar
Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 2014; 64: 938-45.VejpongsaPYehETHPrevention of anthracycline-induced cardiotoxicityJ Am Coll Cardiol2014649384510.1016/j.jacc.2014.06.116725169180Search in Google Scholar
Lainscak M, Haehling S von, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009; 132: 303-11.LainscakMvon HaehlingSAnkerSDNatriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markersInt J Cardiol20091323031110.1016/j.ijcard.2008.11.14919144431Search in Google Scholar
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-54.CardinaleDSandriMTColomboAColomboNBoeriMLamantiaGPrognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapyCirculation200410927495410.1161/01.CIR.0000130926.51766.CC15148277Search in Google Scholar
Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv 2013; 7: 253-61.WeaverKEForakerREAlfanoCMRowlandJHAroraNKBellizziKMCardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care?J Cancer Surviv201372536110.1007/s11764-013-0267-9375680723417882Search in Google Scholar
Patanè S. Cardiotoxicity: Cisplatin and long-term cancer survivors. Int J Cardiol 2014; 175: 201-2.PatanèSCardiotoxicity: Cisplatin and long-term cancer survivorsInt J Cardiol2014175201210.1016/j.ijcard.2014.04.23824820740Search in Google Scholar
Bano N, Najam R, Qazi F. Adverse cardiac manifestations of cisplatin – a review. Int J Pharm Sci Rev Res 2013; 18: 80-5.BanoNNajamRQaziFAdverse cardiac manifestations of cisplatin – a reviewInt J Pharm Sci Rev Res201318805Search in Google Scholar
Khan S, Chen CL, Brady MS, Parameswaran R, Moore R, Hassoun H, et al. Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma. J Clin Oncol 2012; 30: e163-4.KhanSChenCLBradyMSParameswaranRMooreRHassounHUnstable angina associated with cisplatin and carboplatin in a patient with advanced melanomaJ Clin Oncol201230e163410.1200/JCO.2011.38.785222585705Search in Google Scholar
Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatinbased chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29: 3466-73.MooreRAAdelNRiedelEBhutaniMFeldmanDRTabbaraNEHigh incidence of thromboembolic events in patients treated with cisplatinbased chemotherapy: a large retrospective analysisJ Clin Oncol20112934667310.1200/JCO.2011.35.5669681597921810688Search in Google Scholar
Demkow U, Stelmaszczyk-Emmel A. Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Respir Physiol Neurobiol 2013; 187: 64-7.DemkowUStelmaszczyk-EmmelACardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patientsRespir Physiol Neurobiol201318764710.1016/j.resp.2013.03.01323548823Search in Google Scholar
El-Awady E-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatininduced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335-41.El-AwadyE-SEMoustafaYMAbo-ElmattyDMRadwanACisplatininduced cardiotoxicity: mechanisms and cardioprotective strategiesEur J Pharmacol20116503354110.1016/j.ejphar.2010.09.08521034734Search in Google Scholar
Hussein A, Ahmed AAE, Shouman SA, Sharawy S. Ameliorating effect of DL-α-lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animals. Drug Discov Ther 2012; 6: 147-56.HusseinAAhmedAAEShoumanSASharawySAmeliorating effect of DL-α-lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animalsDrug Discov Ther201261475610.5582/ddt.2012.v6.3.147Search in Google Scholar
Schinkel LD van, Willemse PM, Meer RW van der, Burggraaf J, Elderen SGC van, Smit JWA, et al. Chemotherapy for testicular cancer induces acute alterations in diastolic heart function. Br J Cancer 2013; 109: 891-6.SchinkelLDvan, WillemsePMMeerRW van der, BurggraafJElderenSGCvan, SmitJWAChemotherapy for testicular cancer induces acute alterations in diastolic heart functionBr J Cancer2013109891610.1038/bjc.2013.445374958923922115Search in Google Scholar
Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-36.StrumbergDBruggeSKornMWKoeppenSRanftJScheiberGEvaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancerAnn Oncol2002132293610.1093/annonc/mdf05811885999Search in Google Scholar
Altena R, Hummel YM, Nuver J, Smit a J, Lefrandt JD, Boer R a de, et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011; 22: 2286-93.AltenaRHummelYMNuverJSmitaJLefrandtJDBoerRadeLongitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancerAnn Oncol20112222869310.1093/annonc/mdr40821878427Search in Google Scholar
Hardy D, Liu C-C, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 2010; 21: 1825-33.HardyDLiuC-CCormierJNXiaRDuXLCardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancerAnn Oncol20102118253310.1093/annonc/mdq042298094020211871Search in Google Scholar
Wachters FM, Graaf WTA Van Der, Groen HJM. Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. Anticancer Res 2004; 24: 2079- 83.WachtersFMGraafWTAVan Der, GroenHJMCardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatmentAnticancer Res200424207983Search in Google Scholar
Lang RM, Bierig M, Devereux RB, Flachskampf F, Foster E, Pellikka P, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.LangRMBierigMDevereuxRBFlachskampfFFosterEPellikkaPRecommendations for chamber quantificationEur J Echocardiogr200677910810.1016/j.euje.2005.12.01416458610Search in Google Scholar
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth O A, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-93.NaguehSFAppletonCPGillebertTCMarinoPNOhJKSmiseth OARecommendations for the evaluation of left ventricular diastolic function by echocardiographyEur J Echocardiogr2009101659310.1093/ejechocard/jep007Search in Google Scholar
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.SeidmanAHudisCPierriMKShakSPatonVAshbyMCardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol20022012152110.1200/JCO.2002.20.5.1215Search in Google Scholar
Meinardi BMT, Gietema JA, Veldhuisen DJ Van, Runne MA, Sluiter WJ, Mulder NH, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-32.MeinardiBMTGietemaJAVeldhuisenDJVan, RunneMASluiterWJMulderNHCardiovascular morbidity in long-term survivors of metastatic testicular cancerJ Clin Oncol20001817253210.1200/JCO.2000.18.8.1725Search in Google Scholar
S. Gillespie H, J. McGann C, D. Wilson B. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev 2012; 7: 234-44.GillespieS.HMcGannCJWilson D.BNoninvasive diagnosis of chemotherapy related cardiotoxicityCurr Cardiol Rev201272344410.2174/157340311799960672Search in Google Scholar
Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52: 450-9.DanielsLBLaughlinGACloptonPMaiselASBarrett-ConnorEMinimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo StudyJ Am Coll Cardiol200852450910.1016/j.jacc.2008.04.033Search in Google Scholar
Gharib MI, Burnett a K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42.GharibMIBurnett aKChemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxisEur J Heart Fail200242354210.1016/S1388-9842(01)00201-XSearch in Google Scholar
Eschenhagen T, Force T, Ewer MS, Keulenaer GW de, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 1-10.EschenhagenTForceTEwerMSKeulenaerGW deSuterTMAnkerSDCardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyEur J Heart Fail20111311010.1093/eurjhf/hfq21321169385Search in Google Scholar
Patil H, Vaidya O, Bogart D. A review of causes and systemic approach to cardiac troponin elevation. Clin Cardiol 2011; 34: 723-8.PatilHVaidyaOBogartDA review of causes and systemic approach to cardiac troponin elevationClin Cardiol201134723810.1002/clc.20983665269622120679Search in Google Scholar
